Jing Li, Jieyan Luo, Zhanjun Dou, Mingxia Hou. "Acquired resistance to first-line osimertinib is heterogeneous in EGFR-mutant advanced non-small cell lung cancer." Scientific Reports, 2026. doi:10.1038/s41598-026-59570-z